シンポジウム
2021年5月20日(木) 16:15 〜 18:15 第7会場 (国立京都国際会館 1F Room D)
座長：村井 弘之(国際医療福祉大学成田病院脳神経内科学),鈴木 重明(慶應義塾大学医学部神経内科)
Treatment for myasthenia gravis (MG) is drastically changing. High dose and long-term steroid administration is no longer recommended. Instead, early fast-acting treatment using immunoglobulin and/or plasmapheresis has been utilized widely. Recently, molecular targeted drugs have emerged and changing the scene of the MG treatment. In this symposium, we would like to discuss over these new medicines such as complement inhibitors, FcRn inhibitors and B-cell antibodies. Debate on economic issue will also be planned since these drugs are very expensive and could be a big burden to the society.
○Angela Genge1,2 (1.McGill University, 2.Montreal Neurological Institute and Hospital)
スケジュール
いいね！
)
○鵜沢 顕之 (千葉大学大学院医学研究院 脳神経内科学)
スケジュール
いいね！
)
○紺野 晋吾 (東邦大学医学部内科学講座神経内科分野(大橋))
スケジュール
いいね！
)
○Jason L. Crowell1,2 (1.Neurologist, Beth Israel Deaconess Medical Center, 2.Jerome H. Grossman M.D. Graduate Fellow, Harvard Kennedy School)
スケジュール
いいね！
)